These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16611057)

  • 1. Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody.
    Peut V; Kent SJ
    Curr HIV Res; 2006 Apr; 4(2):191-7. PubMed ID: 16611057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
    Kent SJ; Fernandez CS; Dale CJ; Davenport MP
    Trends Microbiol; 2005 Jun; 13(6):243-6. PubMed ID: 15936652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 5. Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.
    Shahid A; Olvera A; Anmole G; Kuang XT; Cotton LA; Plana M; Brander C; Brockman MA; Brumme ZL
    J Virol; 2015 Nov; 89(22):11557-71. PubMed ID: 26355081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses.
    Murakoshi H; Koyanagi M; Chikata T; Rahman MA; Kuse N; Sakai K; Gatanaga H; Oka S; Takiguchi M
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27903797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection.
    Sunshine JE; Larsen BB; Maust B; Casey E; Deng W; Chen L; Westfall DH; Kim M; Zhao H; Ghorai S; Lanxon-Cookson E; Rolland M; Collier AC; Maenza J; Mullins JI; Frahm N
    J Virol; 2015 Oct; 89(20):10303-18. PubMed ID: 26223634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
    Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
    Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
    Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
    J Virol; 2018 May; 92(9):. PubMed ID: 29491151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope.
    Soudeyns H; Paolucci S; Chappey C; Daucher MB; Graziosi C; Vaccarezza M; Cohen OJ; Fauci AS; Pantaleo G
    Eur J Immunol; 1999 Nov; 29(11):3629-35. PubMed ID: 10556818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient.
    Brener J; Gall A; Hurst J; Batorsky R; Lavandier N; Chen F; Edwards A; Bolton C; Dsouza R; Allen T; Pybus OG; Kellam P; Matthews PC; Goulder PJR
    Retrovirology; 2018 Jan; 15(1):7. PubMed ID: 29338738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.
    Price DA; O'callaghan CA; Whelan JA; Easterbrook PJ; Phillips RE
    Clin Sci (Lond); 1999 Dec; 97(6):707-18. PubMed ID: 10585898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV evolution: CTL escape mutation and reversion after transmission.
    Leslie AJ; Pfafferott KJ; Chetty P; Draenert R; Addo MM; Feeney M; Tang Y; Holmes EC; Allen T; Prado JG; Altfeld M; Brander C; Dixon C; Ramduth D; Jeena P; Thomas SA; St John A; Roach TA; Kupfer B; Luzzi G; Edwards A; Taylor G; Lyall H; Tudor-Williams G; Novelli V; Martinez-Picado J; Kiepiela P; Walker BD; Goulder PJ
    Nat Med; 2004 Mar; 10(3):282-9. PubMed ID: 14770175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.
    Locher CP; Grant RM; Collisson EA; Reyes-Terán G; Elbeik T; Kahn JO; Levy JA
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1685-9. PubMed ID: 10606091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.
    Liu Y; McNevin J; Zhao H; Tebit DM; Troyer RM; McSweyn M; Ghosh AK; Shriner D; Arts EJ; McElrath MJ; Mullins JI
    J Virol; 2007 Nov; 81(22):12179-88. PubMed ID: 17728222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.
    Montefiori DC; Altfeld M; Lee PK; Bilska M; Zhou J; Johnston MN; Gao F; Walker BD; Rosenberg ES
    J Immunol; 2003 Apr; 170(7):3906-14. PubMed ID: 12646660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.